These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28361188)

  • 1. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
    Pinker K; Riedl C; Weber WA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):55-66. PubMed ID: 28361188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
    Wahl RL; Jacene H; Kasamon Y; Lodge MA
    J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
    Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
    Kim HD; Kim BJ; Kim HS; Kim JH
    Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
    Min SJ; Jang HJ; Kim JH
    Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
    PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
    Nasir Z; Mahmood T; Adel H; Nausheen S; Hamid S; Sattar A; Manohar M
    Cureus; 2019 Aug; 11(8):e5422. PubMed ID: 31632874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
    Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT
    Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review.
    Kim JH
    Oncotarget; 2016 Sep; 7(36):58105-58110. PubMed ID: 27517621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
    O JH; Lodge MA; Wahl RL
    Radiology; 2016 Aug; 280(2):576-84. PubMed ID: 26909647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
    Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
    Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
    Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
    Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.